Tiziana Life Sciences’ foralumab meets dual primary endpoints in Phase 2a MS trial
TLSA•Tiziana Life Sciences said its Phase 2a INFORM-MS trial of intranasal foralumab met both primary endpoints, showing reduced brain immune-cell activation versus placebo and favorable tolerability. Fatigue also improved on a secondary endpoint.
1. Trial results
The trial in non-active secondary progressive multiple sclerosis met both primary endpoints, showing reduced brain immune-cell activation versus placebo with favorable tolerability. Fatigue improved meaningfully on a secondary endpoint. Tiziana Life Sciences will present the results at the Jefferies Healthcare Conference in London on November 18, 2026; they were previously reviewed during a November 9 key opinion leader call.
